Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Juvenile Dermatomyositis Derails Growth and Pubertal Development

Publish date:: September 30, 2019

Key clinical point: Children in early puberty during the active phase of juvenile dermatomyositis had the highest risk of growth failure.

Major finding: Growth failure occurred in 21% of girls and 15% of boys with juvenile dermatomyositis over the course of a 2-year study.

Study details: The data come from a longitudinal cohort study of 196 children with juvenile dermatomyositis.

Disclosures: The study was supported by the European Union, Helse Nord Research grants, and by IRCCS Istituto Giannina Gaslini. Five authors of the study reported financial relationships with pharmaceutical companies.

Citation:

Nordal E et al. Arthritis Care Res. 2019 Sep 10. doi: 10.1002/acr.24065.

This Week's Must Reads

TULIP trials show clinical benefit of anifrolumab for SLE,

Health care: More uninsured as insurance costs grow faster,

Upadacitinib Doubles ASAS 40 Response VS. Placebo in Ankylosing Spondylitis,

Glucocorticoids Linked to Damage Accrual in SLE Regardless of Disease Activity,

Certolizumab Safety Profile Varies Widely Across Indications,

Must Reads in Pediatrics

AAD-NPF Pediatric Psoriasis Guideline Advises on Physical and Mental Care,

Psoriasis Risk Rises With TNF Inhibitor Use in Children With Inflammatory Disorders,

Marked Increase in Psoriasis Seen With TNFi Use in Pediatric Inflammatory Diseases,

PASI-75 With Ixekizumab Approaches 90% in Pediatric Psoriasis Study,

Anakinra Treatment for Pediatric ‘Cytokine Storms’,